DrugPatentWatch Database Preview
Sofosbuvir; velpatasvir; voxilaprevir - Generic Drug Details
» See Plans and Pricing
What are the generic drug sources for sofosbuvir; velpatasvir; voxilaprevir and what is the scope of freedom to operate?
Sofosbuvir; velpatasvir; voxilaprevir
is the generic ingredient in one branded drug marketed by Gilead Sciences Inc and is included in one NDA. There are fifteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.Sofosbuvir; velpatasvir; voxilaprevir has five hundred and forty-three patent family members in forty-eight countries.
There are nine drug master file entries for sofosbuvir; velpatasvir; voxilaprevir. One supplier is listed for this compound.
Summary for sofosbuvir; velpatasvir; voxilaprevir
International Patents: | 543 |
US Patents: | 15 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Drug Master File Entries: | 9 |
Suppliers / Packagers: | 1 |
Clinical Trials: | 12 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for sofosbuvir; velpatasvir; voxilaprevir |
DailyMed Link: | sofosbuvir; velpatasvir; voxilaprevir at DailyMed |
Recent Clinical Trials for sofosbuvir; velpatasvir; voxilaprevir
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Helwan University | Phase 4 |
Partners in Health | Phase 4 |
Kirby Institute | Phase 4 |
See all sofosbuvir; velpatasvir; voxilaprevir clinical trials
Pharmacology for sofosbuvir; velpatasvir; voxilaprevir
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gilead Sciences Inc | VOSEVI | sofosbuvir; velpatasvir; voxilaprevir | TABLET;ORAL | 209195-001 | Jul 18, 2017 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
Gilead Sciences Inc | VOSEVI | sofosbuvir; velpatasvir; voxilaprevir | TABLET;ORAL | 209195-001 | Jul 18, 2017 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | ||
Gilead Sciences Inc | VOSEVI | sofosbuvir; velpatasvir; voxilaprevir | TABLET;ORAL | 209195-001 | Jul 18, 2017 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for sofosbuvir; velpatasvir; voxilaprevir
Country | Patent Number | Estimated Expiration |
---|---|---|
Costa Rica | 20120532 | Start Trial |
Mexico | 336580 | Start Trial |
Japan | 2010532747 | Start Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for sofosbuvir; velpatasvir; voxilaprevir
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2203462 | CA 2014 00061 | Denmark | Start Trial | PRODUCT NAME: SOFOSBUVIR; REG. NO/DATE: EU/1/13/894/001-002 20140116 |
2203462 | C 2014 043 | Romania | Start Trial | PRODUCT NAME: SOFOSBUVIR; NATIONAL AUTHORISATION NUMBER: EU/1/13/894(001-002); DATE OF NATIONAL AUTHORISATION: 20140116; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/13/894(001-002); DATE OF FIRST AUTHORISATION IN EEA: 20140116 |
2203462 | C02203462/01 | Switzerland | Start Trial | PRODUCT NAME: SOFOSBUVIR; REGISTRATION NO/DATE: SWISSMEDIC 63218 18.03.2014 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:






Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.